Reviews Drospirenone and Estradiol


No reviews yet.

Angeliq Drug Description
ANGELIQ®
(drospirenone and estradiol) Tablets 0.5 mg/1 mg

WARNING
Estrogens with or without progestins should not be used for the prevention
of cardiovascular disease or dementia. (See WARNINGS,
Cardiovascular disorders and Dementia.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated equine estrogens (CE 0.625 mg) combined
with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo (see CLINICAL
PHARMACOLOGY, Clinical Studiesand WARNINGS,
Cardiovascular disorders and Malignant neoplasms, Breast cancer.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 5.2 years of treatment with conjugated estrogens
alone and during 4 years of treatment with oral conjugated estrogens plus
medroxyprogesterone acetate, relative to placebo. It is unknown whether this
finding applies to younger postmenopausal women. (See CLINICAL PHARMACOLOGY,
Clinical Studies, WARNINGS,
Dementia and PRECAUTIONS, Geriatric Use.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate,
and other combinations and dosage forms of estrogens and progestins were not
studied in the WHI clinical trials, and, in the absence of comparable data,
these risks should be assumed to be similar. Because of these risks, estrogens
with or without progestins should be prescribed at the lowest effective doses
and for the shortest duration consistent with treatment goals and risks for
the individual woman.

DRUG DESCRIPTION



What are the possible side effects of drospirenone and estradiol (Angeliq)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using this medication and call your doctor at once if you have any of these serious side effects:

chest pain;
shortness of breath;
sudden numbness or weakness, especially on one side of the body;
sudden headache, confusion, problems with vision, speech, or balance;
...
Read All Potential Side Effects for Angeliq »




ANGELIQ TABLETS provide a hormone regimen consisting of film coated
tablets each containing 0.5 mg of drospirenone and 1 mg of estradiol. The inactive
ingredients are lactose monohydrate NF, corn starch NF, modified starch NF,
povidone 25000 USP, magnesium stearate NF, hydroxylpropylmethyl cellulose USP,
macrogol 6000 NF, talc USP, titanium dioxide USP, and ferric oxide pigment NF.

Drospirenone, (6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)
-1,3┬┤, 4┬┤,6,6a,7,8,9,10,11,12,13,14,15,15a,16-hexadecahydro-10,13- dimethylspiro-[17H-dicyclopropa[6,7:15,16]cyclopenta
[a]phenanthrene-17,2┬┤(5H)-furan]-3,5┬┤(2H)-dione (CAS) is a synthetic
progestational compound and has a molecular weight of 366.5 and a molecular
formula of C24H30O3.
Estradiol USP, (Estra┬ľ1,3,5(10)┬ľtriene┬ľ3,17┬ľdiol,17β), has a molecular
weight of 272.39 and the molecular formula is C18H24O2.
The structural formulas are as follows:







Last reviewed on RxList: 1/16/2009




Angeliq Drug Description
ANGELIQ®
(drospirenone and estradiol) Tablets 0.5 mg/1 mg

WARNING
Estrogens with or without progestins should not be used for the prevention
of cardiovascular disease or dementia. (See WARNINGS,
Cardiovascular disorders and Dementia.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated equine estrogens (CE 0.625 mg) combined
with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo (see CLINICAL
PHARMACOLOGY, Clinical Studiesand WARNINGS,
Cardiovascular disorders and Malignant neoplasms, Breast cancer.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 5.2 years of treatment with conjugated estrogens
alone and during 4 years of treatment with oral conjugated estrogens plus
medroxyprogesterone acetate, relative to placebo. It is unknown whether this
finding applies to younger postmenopausal women. (See CLINICAL PHARMACOLOGY,
Clinical Studies, WARNINGS,
Dementia and PRECAUTIONS, Geriatric Use.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate,
and other combinations and dosage forms of estrogens and progestins were not
studied in the WHI clinical trials, and, in the absence of comparable data,
these risks should be assumed to be similar. Because of these risks, estrogens
with or without progestins should be prescribed at the lowest effective doses
and for the shortest duration consistent with treatment goals and risks for
the individual woman.

DRUG DESCRIPTION



What are the possible side effects of drospirenone and estradiol (Angeliq)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using this medication and call your doctor at once if you have any of these serious side effects:

chest pain;
shortness of breath;
sudden numbness or weakness, especially on one side of the body;
sudden headache, confusion, problems with vision, speech, or balance;
...
Read All Potential Side Effects for Angeliq »




ANGELIQ TABLETS provide a hormone regimen consisting of film coated
tablets each containing 0.5 mg of drospirenone and 1 mg of estradiol. The inactive
ingredients are lactose monohydrate NF, corn starch NF, modified starch NF,
povidone 25000 USP, magnesium stearate NF, hydroxylpropylmethyl cellulose USP,
macrogol 6000 NF, talc USP, titanium dioxide USP, and ferric oxide pigment NF.

Drospirenone, (6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)
-1,3┬┤, 4┬┤,6,6a,7,8,9,10,11,12,13,14,15,15a,16-hexadecahydro-10,13- dimethylspiro-[17H-dicyclopropa[6,7:15,16]cyclopenta
[a]phenanthrene-17,2┬┤(5H)-furan]-3,5┬┤(2H)-dione (CAS) is a synthetic
progestational compound and has a molecular weight of 366.5 and a molecular
formula of C24H30O3.
Estradiol USP, (Estra┬ľ1,3,5(10)┬ľtriene┬ľ3,17┬ľdiol,17β), has a molecular
weight of 272.39 and the molecular formula is C18H24O2.
The structural formulas are as follows:







Last reviewed on RxList: 1/16/2009




Angeliq Drug Description
ANGELIQ®
(drospirenone and estradiol) Tablets 0.5 mg/1 mg

WARNING
Estrogens with or without progestins should not be used for the prevention
of cardiovascular disease or dementia. (See WARNINGS,
Cardiovascular disorders and Dementia.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated equine estrogens (CE 0.625 mg) combined
with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo (see CLINICAL
PHARMACOLOGY, Clinical Studiesand WARNINGS,
Cardiovascular disorders and Malignant neoplasms, Breast cancer.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 5.2 years of treatment with conjugated estrogens
alone and during 4 years of treatment with oral conjugated estrogens plus
medroxyprogesterone acetate, relative to placebo. It is unknown whether this
finding applies to younger postmenopausal women. (See CLINICAL PHARMACOLOGY,
Clinical Studies, WARNINGS,
Dementia and PRECAUTIONS, Geriatric Use.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate,
and other combinations and dosage forms of estrogens and progestins were not
studied in the WHI clinical trials, and, in the absence of comparable data,
these risks should be assumed to be similar. Because of these risks, estrogens
with or without progestins should be prescribed at the lowest effective doses
and for the shortest duration consistent with treatment goals and risks for
the individual woman.

DRUG DESCRIPTION



What are the possible side effects of drospirenone and estradiol (Angeliq)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using this medication and call your doctor at once if you have any of these serious side effects:

chest pain;
shortness of breath;
sudden numbness or weakness, especially on one side of the body;
sudden headache, confusion, problems with vision, speech, or balance;
...
Read All Potential Side Effects for Angeliq »




ANGELIQ TABLETS provide a hormone regimen consisting of film coated
tablets each containing 0.5 mg of drospirenone and 1 mg of estradiol. The inactive
ingredients are lactose monohydrate NF, corn starch NF, modified starch NF,
povidone 25000 USP, magnesium stearate NF, hydroxylpropylmethyl cellulose USP,
macrogol 6000 NF, talc USP, titanium dioxide USP, and ferric oxide pigment NF.

Drospirenone, (6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)
-1,3┬┤, 4┬┤,6,6a,7,8,9,10,11,12,13,14,15,15a,16-hexadecahydro-10,13- dimethylspiro-[17H-dicyclopropa[6,7:15,16]cyclopenta
[a]phenanthrene-17,2┬┤(5H)-furan]-3,5┬┤(2H)-dione (CAS) is a synthetic
progestational compound and has a molecular weight of 366.5 and a molecular
formula of C24H30O3.
Estradiol USP, (Estra┬ľ1,3,5(10)┬ľtriene┬ľ3,17┬ľdiol,17β), has a molecular
weight of 272.39 and the molecular formula is C18H24O2.
The structural formulas are as follows:







Last reviewed on RxList: 1/16/2009




Angeliq Drug Description
ANGELIQ®
(drospirenone and estradiol) Tablets 0.5 mg/1 mg

WARNING
Estrogens with or without progestins should not be used for the prevention
of cardiovascular disease or dementia. (See WARNINGS,
Cardiovascular disorders and Dementia.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated equine estrogens (CE 0.625 mg) combined
with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo (see CLINICAL
PHARMACOLOGY, Clinical Studiesand WARNINGS,
Cardiovascular disorders and Malignant neoplasms, Breast cancer.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 5.2 years of treatment with conjugated estrogens
alone and during 4 years of treatment with oral conjugated estrogens plus
medroxyprogesterone acetate, relative to placebo. It is unknown whether this
finding applies to younger postmenopausal women. (See CLINICAL PHARMACOLOGY,
Clinical Studies, WARNINGS,
Dementia and PRECAUTIONS, Geriatric Use.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate,
and other combinations and dosage forms of estrogens and progestins were not
studied in the WHI clinical trials, and, in the absence of comparable data,
these risks should be assumed to be similar. Because of these risks, estrogens
with or without progestins should be prescribed at the lowest effective doses
and for the shortest duration consistent with treatment goals and risks for
the individual woman.

DRUG DESCRIPTION



What are the possible side effects of drospirenone and estradiol (Angeliq)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using this medication and call your doctor at once if you have any of these serious side effects:

chest pain;
shortness of breath;
sudden numbness or weakness, especially on one side of the body;
sudden headache, confusion, problems with vision, speech, or balance;
...
Read All Potential Side Effects for Angeliq »




ANGELIQ TABLETS provide a hormone regimen consisting of film coated
tablets each containing 0.5 mg of drospirenone and 1 mg of estradiol. The inactive
ingredients are lactose monohydrate NF, corn starch NF, modified starch NF,
povidone 25000 USP, magnesium stearate NF, hydroxylpropylmethyl cellulose USP,
macrogol 6000 NF, talc USP, titanium dioxide USP, and ferric oxide pigment NF.

Drospirenone, (6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)
-1,3┬┤, 4┬┤,6,6a,7,8,9,10,11,12,13,14,15,15a,16-hexadecahydro-10,13- dimethylspiro-[17H-dicyclopropa[6,7:15,16]cyclopenta
[a]phenanthrene-17,2┬┤(5H)-furan]-3,5┬┤(2H)-dione (CAS) is a synthetic
progestational compound and has a molecular weight of 366.5 and a molecular
formula of C24H30O3.
Estradiol USP, (Estra┬ľ1,3,5(10)┬ľtriene┬ľ3,17┬ľdiol,17β), has a molecular
weight of 272.39 and the molecular formula is C18H24O2.
The structural formulas are as follows:







Last reviewed on RxList: 1/16/2009




Angeliq Drug Description
ANGELIQ®
(drospirenone and estradiol) Tablets 0.5 mg/1 mg

WARNING
Estrogens with or without progestins should not be used for the prevention
of cardiovascular disease or dementia. (See WARNINGS,
Cardiovascular disorders and Dementia.)
The Women's Health Initiative (WHI) study reported increased risks of myocardial
infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein
thrombosis in postmenopausal women (50 to 79 years of age) during 5 years
of treatment with oral conjugated equine estrogens (CE 0.625 mg) combined
with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo (see CLINICAL
PHARMACOLOGY, Clinical Studiesand WARNINGS,
Cardiovascular disorders and Malignant neoplasms, Breast cancer.)
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported
increased risk of developing probable dementia in postmenopausal women 65
years of age or older during 5.2 years of treatment with conjugated estrogens
alone and during 4 years of treatment with oral conjugated estrogens plus
medroxyprogesterone acetate, relative to placebo. It is unknown whether this
finding applies to younger postmenopausal women. (See CLINICAL PHARMACOLOGY,
Clinical Studies, WARNINGS,
Dementia and PRECAUTIONS, Geriatric Use.)
Other doses of oral conjugated estrogens with medroxyprogesterone acetate,
and other combinations and dosage forms of estrogens and progestins were not
studied in the WHI clinical trials, and, in the absence of comparable data,
these risks should be assumed to be similar. Because of these risks, estrogens
with or without progestins should be prescribed at the lowest effective doses
and for the shortest duration consistent with treatment goals and risks for
the individual woman.

DRUG DESCRIPTION



What are the possible side effects of drospirenone and estradiol (Angeliq)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Stop using this medication and call your doctor at once if you have any of these serious side effects:

chest pain;
shortness of breath;
sudden numbness or weakness, especially on one side of the body;
sudden headache, confusion, problems with vision, speech, or balance;
...
Read All Potential Side Effects for Angeliq »




ANGELIQ TABLETS provide a hormone regimen consisting of film coated
tablets each containing 0.5 mg of drospirenone and 1 mg of estradiol. The inactive
ingredients are lactose monohydrate NF, corn starch NF, modified starch NF,
povidone 25000 USP, magnesium stearate NF, hydroxylpropylmethyl cellulose USP,
macrogol 6000 NF, talc USP, titanium dioxide USP, and ferric oxide pigment NF.

Drospirenone, (6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)
-1,3┬┤, 4┬┤,6,6a,7,8,9,10,11,12,13,14,15,15a,16-hexadecahydro-10,13- dimethylspiro-[17H-dicyclopropa[6,7:15,16]cyclopenta
[a]phenanthrene-17,2┬┤(5H)-furan]-3,5┬┤(2H)-dione (CAS) is a synthetic
progestational compound and has a molecular weight of 366.5 and a molecular
formula of C24H30O3.
Estradiol USP, (Estra┬ľ1,3,5(10)┬ľtriene┬ľ3,17┬ľdiol,17β), has a molecular
weight of 272.39 and the molecular formula is C18H24O2.
The structural formulas are as follows:







Last reviewed on RxList: 1/16/2009





Other reviews about Drospirenone and Estradiol on wordpress

New Hormone Therapy approved for Menopause
  by rampress
Although this blog brings you mostly news for the male, there are times when a major piece of information or news may be of interest to both sexes. […]


Acne therapy
  by doctme
Acne vulgaris Acne vulgaris is a chronic disorder of the pilosebaceous apparatus caused by abnormal desquamation of follicular epithelium leading to obstruction of the pilosebaceous canal, resulting in inflammation […]


Is Yaz / Yasmin to blame for deaths and injuries in young women?
  by Zach Thomas
A Nashville family is alleging that the birth control medication Yaz / Yasmin has claimed the life of their 20-year-old daughter.┬á Litigation continues to build against Bayer as […]


Canadian women allege that birth control Yaz / Yasmin / Ocella caused sever health problems
  by Zach Thomas
Yesterday, a lawsuit was filed in Canada against Bayer.┬á In the lawsuit, a group of women allege that Yaz / Yasmin / Ocella has caused severe harm to […]


Bayer lowers estimates for pharma sales after Yaz decline
  by orderviagrauk
Bayer has posted a 63.1% rise in net income for the first quarter to 693 million euros, but the Leverkusen-based firmÔÇÖs pharmaceutical sales were disappointing. Earnings before interest, taxes, […]


FDA approves new, "safe?" birth control pill
  by healthnewsforyou
I recently came across an article in WebMd Health News about the FDA's approval of a new birth control pill. Natazia (or Qlaira in Europe), is "the first four […]


FDA MedWatch - April 2010 - Drug Safety Labeling Changes
  by irbtipoftheweek
The MedWatch April 2010 Drug Safety Labeling Changes posting includes 44 products with safety labeling changes to the following sections: BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, PATIENT […]


Hormonal Contraceptives and Acne
  by thescienceofacne
Many women report significant changes in the frequency and severity of their acne outbreaks after beginning a program of hormonal contraceptives. ┬áFor many women the use hormonal birth […]


Oral Contraceptives with Added Folate
  by drppanda
FDA has approved addition of folate to oral contraceptives with an intent to decrease some birth defects in their babies. This is levomefolate calcium.Amplify’d from www.medscape.comFDA Approves Oral […]



Other reviews about Drospirenone and Estradiol on web:

Physician reviewed drospirenone and ethinyl estradiol patient information - includes drospirenone and ethinyl estradiol description, dosage and directions. drospirenone and ethinyl estradiol medical facts from Drugs.com


Mayo Clinic offers award-winning medical and health information and tools for healthy living. Drospirenone and Estradiol (Oral Route) - MayoClinic.com


All about Drospirenone/Estradiol Tablets. View complete and up to date Drospirenone/Estradiol information - part of the Drugs.com trusted medication database. Drospirenone/Estradiol Tablets Facts and Comparisons at Drugs.com


Mayo Clinic offers award-winning medical and health information and tools for healthy living. Drospirenone and Ethinyl Estradiol (Oral Route) - MayoClinic.com


Drospirenone and Ethinyl Estradiol is a type of birth control pill that combines two hormones: the lowest dosage of ethinyl estradiol commonly used today and drospirenone, a ... Drospirenone and Ethinyl Estradiol - Medpedia


Consumer information about the medication ETHINYL ESTRADIOL/DROSPIRENONE - ORAL (Yasmin 28), includes side effects, drug interactions, recommended dosages, and storage information. ETHINYL ESTRADIOL/DROSPIRENONE - ORAL (Yasmin 28) side effects ...


Drospirenone is a synthetic progestin that is an analog to spironolactone, with a molecular ... in medication to manage menopausal symptoms using 0.5 mg drsp and 1 mg estradiol per day ... Drospirenone - Wikipedia, the free encyclopedia


Learn about the prescription medication Yasmin (Drospirenone and Ethinyl Estradiol), drug uses, dosage, side effects, drug interactions, warnings, and patient labeling. Yasmin (Drospirenone and Ethinyl Estradiol) Drug Information: Uses ...


Learn about the prescription medication Angeliq (Drospirenone and Estradiol), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient labeling. Angeliq (Drospirenone and Estradiol) Drug Information: Uses, Side ...


Estradiol is a female hormone involved in development and maintenance of the female reproductive system. estradiol-drospirenone Information - Drugs and Treatments - MedHelp





Featured Reviews

Reviews Eltrombopag Tablets

Promacta Drug Description PROMACTA® (eltrombopag) Tablets WARNING: RISK FOR HEPATOTOXICITY PROMACTA may cause hepatotoxicity: Measure serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin prior...
Read More  |  Review This
Reviews Papaverine Injection

Papaverine Injection Drug Description PAPAVERINE HYDROCHLORIDE INJECTION, USP This product is to be used by or under the direction of a physician. Each vial contains a sufficient amount to permit withdrawal and administration of the volume...
Read More  |  Review This
Reviews Ibritumomab Tiuxetan

Zevalin Drug Description ZEVALIN® (ibritumomab tiuxetan) Injection for Intravenous Use WARNING SERIOUS INFUSION REACTIONS, PROLONGED AND SEVERE CYTOPENIAS, and SEVERE CUTANEOUS AND MUCOCUTANEOUS REACTIONS Serious Infusion Reactions:...
Read More  |  Review This
Reviews Kuvan

Kuvan Drug Description Kuvan (sapropterin dihydrochloride) Tablets DRUG DESCRIPTION What are the possible side effects of sapropterin (Kuvan)? If sapropterin is not controlling your condition properly, you may have symptoms such...
Read More  |  Review This
Reviews Natacyn

Natacyn Drug Description Natacyn® (natamycin) Ophthalmic Suspension 5% Sterile DRUG DESCRIPTION What are the possible side effects of natamycin ophthalmic (Natacyn)? Serious side effects are not expected with this medication. Commonly,...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....